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Purpose: This study investigated the association between radiation dose and
complication rate in patients who underwent breast reconstruction to understand the role
of radiation hypofractionated regimen, boost radiation therapy (RT), and RT techniques.
Methods: We retrospectively evaluated 75 patients treated with post-mastectomy
adjuvant RT for breast cancer in the setting of two-stage prosthetic breast reconstruction.
Near maximum radiation dose (Dmax) in the 2 or 0.03 cc of reconstructed breast or
overlying breast skin was obtained from dose-volume histograms.
Results: Post-RT complications occurred in 22.7% of patients. Receiver operating
characteristic analysis showed that all near Dmax parameters were able to predict
complication risk, which retained statistical significance after adjusting other variables
(odds ratio 1.12 per Gy, 95% confidence interval 1.02–1.23) with positive dose-response
relationship. In multiple linear regression model (R2 = 0.92), conventional fractionation
(β = 11.7) and 16 fractions in 2.66Gy regimen (β = 3.9) were the major determinants of
near Dmax compared with 15 fractions in 2.66Gy regimen, followed by utilization of boost
RT (β = 3.2). The effect of bolus and dose inhomogeneity seemed minor (P > 0.05). The
location of hot spot was not close to the high density metal area of the expander, but
close to the surrounding areas of partially deflated expander bag.
Conclusions: This study is the first to demonstrate a dose-response relationship
between risk of complications and near Dmax, where hypofractionated regimen or boost
RT can play an important role. Rigorous RT-quality assurance program and modification
of dose constraints could be considered as a critically important component for ongoing
trials of hypofractionation. Based on our findings, we initiated a multi-center retrospective
study (KROG 18-04) and a prospective study (NCT03523078) to validate our findings.
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INTRODUCTION
Breast reconstruction provides important psychosocial, cosmetic,
and quality of life benefits for women undergoing mastectomy
(1, 2), which accounts for approximately more than 60%
of mastectomy women in the US (3). As recent evidence
has widened the indications of post-mastectomy radiation
therapy (RT) to early-stage node-positive breast cancer (4),
an increasing number of patients is currently referred for
adjuvant RT to the reconstructed breast, which has put treating
physicians in a challenging situation. There is substantial
evidence from small case series and prospective cohort studies
demonstrating that RT significantly increases complications
following breast reconstruction regardless of the type of
reconstructive surgery and timing of surgery (5, 6). Breasts
reconstructed with implants are known to be more susceptible to
RT-related complications compared with breasts reconstructed
with autologous tissue (7). However, autologous approaches,
which are resource- and labor-intensive and harbor a potential
risk of acute morbidity, are not always feasible. Significant
advances have been made in reconstructive surgical technique.
Therefore, RT to prosthetic breast reconstruction is no longer
contraindicated (3, 8).
RT has changed a little from 50Gy for 5–6 weeks over
the last several decades. Conventional planning for breast RT
typically includes two tangential fields targeted to the whole
breast or chest wall at an angle. Because of the conical shape
of the breast, the radiation should traverse farther through
the chest wall than the nipple areas, which inevitably causes
significantly higher dose and dose inhomogeneity throughout
the whole breast tissue. Because women’s breasts differ in size
and shape, the degree and location of “hot spot” doses in
the breast are all different. In a recent retrospective study,
researchers found that patients who developed reconstruction-
related complications following post-mastectomy radiotherapy
have higher degree of hot spots in breast skin than patients
without complications, despite the same conventional RT
technique at the same institution (9). This finding suggests
a possible relationship between radiation hot spot doses
and reconstruction-related complications, which can be more
clinically relevant in contemporary practice where modulation of
RT dose and homogeneity is available from dose/fractionation to
treatment planning.
We hypothesized that the level of hot spot dose in
skin or reconstructed-breast region might be associated with
reconstruction-related complications in an independent manner.
In the process of adopting hypofractionation for breast cancer
at our institution between 2012 and 2016, three different
dose/fraction schedules had been used with different RT
delivery techniques with or without individualized boost
irradiation to risky area, while surgical technique of two-
stage prosthetic breast reconstruction was consistent among
plastic surgeons during the same time period. In this context,
we attempted to test our hypothesis in post-mastectomy
patients who underwent RT to the breast with tissue expanders
and planned to exchange the expander for a permanent
implant afterwards.
MATERIALS AND METHODS
Patients
Patients diagnosed with invasive breast cancer between January
of 2012 and December of 2016 who underwent mastectomy with
expander placement followed by post-mastectomy RTwith intent
to replace expander to implant-based reconstruction on a later
date were included in this study. To control the possible effects
of differing types of reconstruction and surgeon experience, this
study was only limited to patients treated with immediate two-
stage prosthetic reconstruction using acellular dermal matrix
(ADM) by experienced plastic surgeons (DL and SS). During
the study period, 1,552 patients underwent total mastectomy,
879 patients simultaneously underwent breast reconstruction
and 504 patients subsequently received RT postoperatively at
our institution. Patients with autologous reconstructions were
excluded, yielding 75 patients. The study was approved by
the Institutional Review Board of Severance Hospital, Yonsei
University Health System.
Breast Reconstruction
The first stage of the operation was performed simultaneously
with the total unilateral mastectomy done by the oncologic
surgery team. An expander was then inserted below the pectoralis
muscle, slung with ADM to cover and reinforce the lower pole of
the breast, and gradually inflated as much as possible. Inflation
of expander started 2 weeks after the first operation, and the
expander was partially deflated before post-mastectomyRT. After
at least 3 months after completion of RT, the second stage of
the operation including an exchange of expander to permanent
implant was performed. In all cases, anatomical implants were
used as a permanent implant.
Radiation Therapy
RT was provided within 6 weeks after mastectomy or completion
of the last cycle of adjuvant chemotherapy. All breast cancer
patients underwent simulation computed tomography (CT)
scans for RT planning. In cases with left-sided tumors and
planned to undergo 3D-conformal RT, CT scans were acquired in
both free breathing and deep inspiration breath hold phases using
a respiration-monitoring device (Abches; APEX Medical, Inc.,
Tokyo, Japan) (10). The clinical target volume (CTV) including
the ipsilateral chest wall, mastectomy scar, and regional nodal
basins including axillary nodes, internal mammary lymph nodes,
and supraclavicular lymph nodes was contoured in all patients
according to the Radiation Therapy Oncology Group (RTOG)
(11) or the European Society for Radiotherapy and Oncology
(ESTRO) target volume guideline (12).
In conventional fractionation RT, chest wall was irradiated
with two tangential photon beams and supraclavicular node with
anterior photon beam with 50.4Gy in 28 fractions. Field-in-field
and wedge methods were used to improve dose homogeneity at
the discretion of the treating physician. Bolus material was used
in patients who have a high risk of skin recurrence to ensure that
skin was covered adequately at the discretion of the physician.
In hypofractionated RT, the prescription dose was 40.05Gy
in 15 daily fractions of 2.67Gy [UK START B regimen (13)]
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or 42.56Gy in 16 daily fractions of 2.66Gy [Canada Ontarian
regimen (14)]. Bolus material was used in patients who had thin
chest wall. The ventral border of chest wall CTV was moved
5mm under the skin surface unless patients had T4 tumors.
Use of arc-based intensity-modulated radiation therapy (IMRT)
(Elekta Infinity Linac, Elekta, Crowley, UK) was recommended
in hypofractionated schedule according to a national guideline
for breast cancer radiation therapy.
At least 95% of the PTV should be covered by the 95%
of the prescribed dose. Minimizing the occurrence of hot spot
(Dmax [maximum point dose] < 105–107%) was strongly
recommended particularly in chest wall skin PTV. The volume
of ipsilateral lung at or exceeding 5Gy (V5) and 20Gy (V20)
was mandated to be ≤45 and ≤20%, respectively, and mean
heart dose to be >3Gy in right-sided tumors and >5Gy in
left-sided tumors. Contralateral breast was constrained to be
>1Gy as a mean dose. Either concomitant or sequential boost
radiation (6–10Gy) was selectively used in patients with positive
resection margin or residual or high-risk lymph node (e.g.,
internal mammary lymph nodal basin).
Study Endpoints
The primary outcome measured was defined as reconstruction-
related complication following reconstructive surgery at any time
after the completion of post-mastectomy RT. Complications
included capsular contracture, wound infection, wound
dehiscence with implant exposure, and others, which required
an unplanned operation or hospitalization. The complications
were evaluated by two independent and blinded plastic surgeons.
Various secondary outcomes measured were collected including
radiation dermatitis based on Common Terminology Criteria for
Adverse Events (version 4.0), survival, and recurrence outcomes.
Analysis
Composite plans were created in MIM software (version 6.7.1;
MIM Software Inc., Cleveland, OH, USA) by integrating
all contours and dose distributions of patients in every RT
session including baseline and adaptive cone down plans to
display cumulative recalculated radiation dose. Skin volume was
individually contoured as a 5mm strip of skin over the tissue
expander (Figure 1A) (15).
Near maximum dose (near Dmax) in the structure was
calculated from 0.03 and 2 cc for regions of high absorbed
dose (D0.03cc and D2cc, respectively), rather than one single
voxel point (point Dmax), as a more clinically relevant dose
parameter. Near Dmax of skin over the expander (skin near
Dmax) and structure surrounding the entire expander (chest
wall clinical target volume near Dmax) was obtained from dose-
volume histograms.
The predictive values of each parameter for development
of complication were tested using receiver operating
characteristic (ROC) method. Logistic regression analysis
was used to perform univariate and multivariate analyses
and to analyze the dose-response relationship between the
complication rate and dosimetric parameter. A multiple
linear regression model was used to examine the effect of
each factor on determining near Dmax. All statistical tests
were two-sided, and a P < 0.05 was considered statistically
FIGURE 1 | Contoured structures for reconstructed breast radiation therapy (A). Red, 5mm strip of the skin over the reconstructed breast; green, chest wall clinical
target volume including the skin. The location of hot spot (107% of the prescribed dose) in partially deflated expander bag (B,C) and in fully inflated expander bag (D).
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significant. Statistical analyses were conducted using R software
packages (http://www.r-project.org).
RESULTS
Baseline Characteristics
A total of 75 patients were included. Baseline characteristics
are summarized in Table 1. The average breast volume was
350 ± 136ml. Seven percent of the patients had a history
of diabetes. Four patients (5%) were former smokers, and
no patient was current smoker at diagnosis. The median
body mass index was 21.6 ± 2.9. A total of 38 (50.7%)
patients had stage III disease, and 39 patients (52%) received
neoadjuvant chemotherapy. In all patients, expander with ADM
was inserted at the time of mastectomy. All patients received
post-mastectomy RT to the chest wall and regional lymph nodes
comprehensively including internal mammary node, axillary
node, and supraclavicular lymph node. A bolus of 0.5 cm
was applied in 25 patients (33.3%) in everyday settings until
tolerated (median 37Gy, range 18–50Gy). Fifty patients received
radiotherapy in hypofractionated schedules, and 25 patients
received RT in conventional fractionation.
Acute Radiation Dermatitis
Grades 1 (faint erythema or dry desquamation), 2 (moderate to
brisk erythema or patchy moist desquamation, mostly confined
to skin folds), and 3 (moist desquamation, in areas other than
skin folds) skin reaction occurred during or after RT in 33 (44%),
10 (13.3%), and 4 (5.3%) patients, respectively.
Post-RT Reconstruction-Related
Complication
Median follow-up was 32.5 months (range, 17.2–72.5 months);
conventional RT vs. hypofractionated RT, 44 months (range,
17.6–72.5 months) vs. 30 months (range, 17.2–47.2 months,
P = 0.002). Complications following reconstructive surgery at
any time after the completion of RT occurred in 17 of 75
patients (22.7%). The complications in the conventional RT
group included Baker grade III and IV capsular contractures
(n = 8), wound dehiscence with implant exposure (n =
3), peri-prosthetic infection (n = 2), cellulitis (n = 1), and
the conditions that required major revisional surgery such as
coverage with latissimus dorsi flap (n = 2). The complications
in the hypofractionated RT group included capsular contractures
(n = 4) and cellulitis (n = 3). The mean time to complication
from the date of RT completion was 8.1 ± 4.9 months. The
complication rate was lower in patients with hypofractionated
RT (14.3%) than in patients with conventional RT (38.5%, P =
0.017). A positive correlation was found between the severity
of acute radiation dermatitis and complication rate [dermatitis
G0 3/28 (10.7%), G1 5/33 (15.2%), G2 7/10 (70%), and G3 2/4
(50%), P < 0.001].
Dosimetric Analysis
ROC analysis showed that “near Dmax,” such as doses to the
hottest 0.03 and 2 cc of chest wall clinical target volume
and skin, was able to predict development of both grade
TABLE 1 | Patient and treatment characteristics (N = 75).
N %
Age, years Median (IQR) 40 (10)
≤40 39 52
>40 36 48
BMI, kg/m2 Median (IQR) 21.6 (2.9)
DM Yes 5 7
Smoking history Ex-smoker 4 5
Current smoker 0 0
Histology IDC 63 84
Others 12 16
Laterality Left 25 33
Right 50 67
Bilateral disease Bilateral 7 9
Final stage* I 2 3
IIA 16 21
IIB 19 25
IIIA 20 27
IIIB 2 3
IIIC 16 21
Grade I 9 13
II 47 65
III 16 22
Molecular subtype Luminal A 28 37
Luminal B (HER2 negative) 18 24
Luminal B (HER2 positive) 8 11
HER2 positive (non-luminal) 9 12
Triple negative 12 16
Breast volume (cc) Left (median, IQR) 321 (205)
Right (median, IQR) 334 (207)
RT Fraction
schedule
267 cGy × 15 45 60
267 cGy × 16 5 7
180 cGy × 28 (200 cGy × 25) 25 33
RT plan 3D CRT 36 48
VMAT 39 52
Boost RT Yes 13 17
Chest wall 5
IMN chain 7
SCL/AXL 1
No 62 83
Use of bolus
material
Yes 25 33
No 50 67
Neoadj chemo No 36 48
Anthracycline based 2 3
Taxane based 26 35
Taxane + HER2 directed therapy 11 15
Adj chemo No 45 60
Taxane non-containing 3 4
Taxane containing 27 36
HER2-directed
therapya
17 100
(Continued)
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TABLE 1 | Continued
N %
Endocrine
therapyb
No 1 2
Tamoxifen 43 80
Tamoxifen + LHRH agonist 6 11
Aromatase inhibitor 4 7
IQR, interquartile range; BMI, bodymass index; DM, diabetes mellitus; IDC, invasive ductal
carcinoma; HER2, human epidermal growth factor receptor 2; RT, radiation therapy;
3D CRT, three-dimensional conformal radiation therapy; VMAT, volumetric arc therapy;
IMN, internal mammary node; SCL/AXL, supraclavicular/axillar lymph node, Neoadj,
neoadjuvant; Adj, adjuvant; LHRH, Luteinizing hormone-releasing hormone.
*Higher of pathologic or prechemotherapy clinical stage.
a100% of patients with HER2-positive disease.
b100% of patients with hormone receptor-positive disease.
≥2 acute radiation dermatitis and post-RT reconstruction
complication (Figure 2). To test the robustness of this
finding, ROC analyses were re-performed after conversion
to an equivalent dose in 2-Gy fractions (α/β = 10 or
3) considering the various fractionation schedules used.
Similar results have been observed regardless of dose
conversion (Supplementary Figure 1).
Near Dmax (skin D2cc) retained statistical significance after
adjusting other variables (odds ratio 1.12; Table 2). Conventional
fractionation regimen (control, 2.66Gy × 15 fraction regimens;
β = 11.7) was a major determinant of near Dmax level,
followed by 2.66Gy × 16 fraction hypofractionation regimens
(control, 2.66Gy × 15 fraction regimens; β = 3.9), and use
of boost RT (β = 3.2, R2 = 0.92, P < 0.001, Table 3). Using
these three factors, the patients can be sorted in ascending
order by near Dmax between 40 and 70Gy (Figure 3A).
Although use of IMRT or tissue-equivalent bolus material
did not significantly influence on the hottest dose level in
the multiple linear regression model, use of bolus changed
the near Dmax level ∼1–3Gy in 3-dimensional conformal
RT (3DCRT) patients, but not in IMRT patients, under
the same condition of fractionation regimen (Figure 3B).
The dose-response relationship between reconstruction-related
complication and skin D2cc was analyzed and the probability
increased as the dose increased (Figure 4). The location of
the radiation hot spot was investigated, and it was not
close to the high density metal area of the expander but
close to the surrounding areas of partially deflated expander
bag (Figures 1B–D).
Recurrence
During the follow-up period, no local recurrence was found
in the chest wall. There were 7 distant metastases with
simultaneous regional recurrence (n = 1) and 2 cancer-related
deaths. The 3-year overall and disease-free survival rates were
97.1 and 89.2%, respectively. The 3-year disease-free survival
rates were 82.6% (95% CI, 66.7–98.5%) and 93.8% (95% CI,
86.9–100%) in the conventional RT and hypofractionated RT
groups, respectively.
DISCUSSION
Although there have been outstanding advances in reconstructive
procedures and materials, post-mastectomy RT remains to have
a profound impact on complications specifically related to
reconstruction (16). In post-mastectomy setting, there was not
much to change regarding RT regimen and techniques (which
govern the dose homogeneity), since RT dose and techniques
have not changed greatly and fixed on 25 fractions of 2Gy per
fraction over the last several decades.
The present retrospective analysis included 75 patients
with breast cancer treated with two-stage prosthetic breast
reconstruction and post-operative radiation. As mentioned
in the Introduction section, a consistent discrepancy exists
regarding RT technique and fractionation schedule among
physicians in our institution from 2012 to 2016. Some physicians
prefer conventional fractionation regimen with standard tangent
techniques, whereas others prefer hypofractionated regimen (15–
16 fractions of 2.66Gy) with IMRT technique. As a result,
the present study included patients treated with a wide range
of radiation dose, which allows to analyze the association of
radiation dose with complication risk. We found a spectrum of
post-RT reconstruction-related complications depending on near
Dmax in the reconstructed breast.
This finding is in line with recent observations by Muresan
et al. from 83 patients with implant-based reconstructions
showing that increased maximum skin dose (D1cc) is associated
with complications (9). Prone positioning technique was
suggested to be used to decrease the maximum skin dose than
supine positioning (58.5Gy vs. 61.7Gy, P < 0.001). Given that
radiation hot spot level is determined by the combination of
prescribed radiation dose and dose inhomogeneity, the present
study discovered the former aspect to complication, and the study
of Muresan et al. highlighted the latter aspect.
The rationale for hypofractionated regimen stemmed from
the emerging evidence that breast cancer cells are more sensitive
to increased daily fraction size. Multiple randomized trials
investigated progressively more condensed regimens (15–16
fractions of 2.66Gy 13→ fractions of 3/3.2/3.33Gy→ 5 fractions
of 5.2–5.4Gy) for breast cancer (mostly in patients with intact
breast who underwent breast conservation therapies) (17). All
hypofractionated regimens have equivalent local control effect to
conventional fractionation regimen (18–21). Based on these data,
the ASTRO guideline has been recently updated to expand the
population of patients recommended to receive hypofractionated
regimen (22). Nonetheless, hypofractionated regimens have been
adopted slowly in Korea and the United States where fear of
large daily fraction dose is deep-seated and fee-for-service is
used (23, 24).
Data supporting hypofractionated RT after mastectomy are
limited, especially if accompanied by breast reconstruction. The
transformative effect of hypofractionated RT in patients with
breast conservation therapies has also accelerated investigation of
hypofractionated RT in the setting ofmastectomywith or without
reconstruction. In 2017, the study of Khan et al. involving
69 patients with stage II to IIIa reported promising results of
hypofractionated post-mastectomy radiotherapy using standard
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TABLE 2 | Unadjusted and adjusted odds ratios for association with reconstruction-related complications for each patient and treatment characteristic.
Univariable Multivariable
OR 95% CI P OR 95% CI P
Age, year (Continuous) 0.98 0.92–1.04 0.533 1.01 0.94–1.07 0.857
Body mass index, kg/m2 (Continuous) 0.84 0.67–1.06 0.143 0.81 0.61–1.07 0.138
Smoking history Yes vs. No 1.15 0.11–11.8 0.909 0.6 0.05–7.02 0.688
Skin D2cc, Gy (Continuous) 1.11 1.02–1.22 0.018 1.12 1.02–1.23 0.015
OR, odds ratio; CI, confidence interval; D2cc, maximum dose in the most exposed tissues of the skin (2 cc).
FIGURE 2 | Receiver operating characteristic (ROC) curve and comparison of dosimetric parameters for development of (A) grade 2+ radiation dermatitis and (B)
post-RT reconstruction-related complication between the areas under the ROC curve. AUC, area under curve; CW, chest wall; CI, confidence interval.
FIGURE 3 | (A) Near Dmax values according to fractionation regimen and use of boost RT. HF (15), 15 fractions in 2.66Gy; HF (16), 16 fractions in 2.66Gy; CF,
conventional fractionation. (B) Near Dmax values according to RT techniques and use of bolus material. CTV, clinical target volume; IMRT, intensity-modulated RT;
3DCRT, 3-dimensional conformal RT.
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TABLE 3 | Coefficients entered in multiple linear regression model for radiation
therapy variables and dose in the most-exposed 2 cc of skin (D2cc).
Variable entered in model ß coefficient SE P-value
180 cGy × 28 (200 cGy × 25) vs. 267 cGy × 15 11.73 0.59 <0.001
267 cGy × 16 vs. 267 cGy × 15 3.85 0.9 <0.001
Use of boost RTa 3.20 0.57 <0.001
3DCRT vs. IMRT 0.86 0.58 0.138
Use of bolus material 0.13 0.48 0.790
Intercept 40.13 0.79
Adjusted R2 0.92 <0.001
SE, standard error; 3DCRT, three-dimensional conformal radiation therapy; IMRT,
intensity-modulated radiation therapy.
aChest wall boost (n= 5), internal mammary node boost (n= 7), and supraclavicular node
boost (n = 1).
FIGURE 4 | Dose-response relationship between skin D2cc and development
of reconstruction-related complication. Shaded gray regions indicate the 95%
confidence interval.
tangent techniques (11 fractions of 3.33Gy) with low toxicity
and high local control (20). Reconstruction was performed in
41 patients, and an overall grade 3 or more reconstruction
toxicity of 32% was observed, which is in line with previously
reported rates. Another 2009 study from the United Kingdom,
where hypofractionation has been commonplace, compared
the risk of capsular contracture between 41 women receiving
hypofractionation (15 factions of 2.66Gy) and 137 without RT
in the setting of implant-based reconstruction (25). The toxicity
rate was significantly higher in RT arm for a crude rate of
19.5% and up to 30% at 5 years. In 2019, a randomized, phase
3 trial in China found the equivalent efficacy and toxicity of
43.5Gy in 15 fractions of hypofractionated RT compared with
conventional treatment in patients with mastectomy without
breast reconstruction (26).
A variety of hypofractionated regimens has been tested
worldwide. Some regimens, such as 13 fractions of 3.3Gy,
where total dose is greater than conventional fractionation
regimen when converted into biological equivalent dose (BED),
were associated with more breast shrinkage, distortion, and
induration, among women irradiated to the intact breast. Other
regimens, such as 15 fractions of 2.66Gy, which is expected to
have lower BED than conventional fractionation, were associated
with less induration, shrinkage, and edema. We identified
a positive dose-response relationship between reconstruction-
related complication and radiation dose (adjusted odds ratio,
2.22 per 5Gy increase; 95% CI 1.36–3.61), and the different
hypofractionation regimens were found to have greatest impact
on the degree of radiation dose. Individualized boost RT (median
8Gy) was used in 17% of our patients to treat microscopic tumor
cells in localized high-risk area. Use of boost RT contributed to
increase radiation hottest dose as the third priority in multiple
linear regression analysis (β= 3.20).
In contrast to the study by Muresan et al. we did not
find a significant difference in hot point dose by different
RT techniques because the hottest dose was strictly restricted
under 105–107% of prescription dose regardless of RT technique
according to institutional dose constraint policy. Even in
patients treated with standard tangent techniques, field-in-field
or wedge technique was used to improve dose homogeneity.
Upcoming randomized trials of hypofractionation (Alliance
A221505, NCT03414970, and FABREC, NCT03422003) are
initiated to compare the complication rate or patient-reported
outcomes of hypofractionated RT and conventional RT in
mastectomy patients with reconstruction. However, considering
our findings, there is an increasing concern about whether
possible confounders will be adequately controlled to compare
two schemes, because in an earlier phase II study (20), a
maximum prescription dose of 120%was allowed within the limit
of 2 cc, which contains a risk of higher maximum point dose
more than 120%. Therefore, dose homogeneity, fractionation
regimen, and use of boost RT should be considered in clinical
trials investigating the RT effect on reconstruction.
Unlike RT to intact breast after breast conservation surgery,
skin is generally included to radiation target in the post-
mastectomy RT setting. Although a tissue-equivalent bolus
material is generally used to increase skin dose by overcoming
the build-up phenomenon, the use of bolus material did
not significantly increase the hottest dose in the skin, which
is estimated from the radiation treatment planning system.
Considering that 1–3Gy variation was observed in patients
treated with 3DCRT, but not in IMRT, the discrepancy can be
explained by a large proportion (52%) of IMRT delivery in the
present cohort because dose to skin is more dependent on target
volume contouring whether the ventral border of breast target
volume delineated 3–5mm under the skin surface or not.
In the present study, severity of RT-related dermatitis
significantly correlated with post-RT complication risk (G0-
1 vs. G2+; 13.1% vs. 64.3%, P < 0.001), which provided
indirect evidence of dose-response relationship hypothesis. This
is explicitly in line with the study by Parsa et al. that acute RT-
related change could be a valid predictive marker for modified
Baker grade IV capsular contracture in 27 patients who were
undergoing delayed expander-implant reconstruction (27). Poor
cosmetic outcomes were observed after reconstruction in more
than three-fourths of the 15 patients who developed severe
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skin changes or induration by RT. However, no poor aesthetic
outcome was found in 27 patients with non-irradiated chest
walls and in 12 patients who received irradiation to chest wall
but had no induration and moderate skin changes. Considering
that several factors including patient’s scarring tendency and a
chronic inflammatory process contribute to the development
of reconstruction complication, such as capsular contracture
(28), radiation is well-known to induce inflammation so that
the severity of radiation dermatitis can be a good surrogate of
post-RT complication risk.
The second indirect evidence of our hypothesis is that
the location of the hottest radiation dose area was close to
the crumpled area of the deflated expander bag in patients
whose expander bag was partially deflated immediately before
RT simulation (Figures 1B–D). It avoids the possibility of
calculation artifact in the planning system, but implies a true “hot
spot” region in tissue. No international consensus on expander
inflation/deflation status during RT has been established. Details
of RT for patients who underwent mastectomy and breast
reconstruction vary widely, according to a recent nationwide
survey in the US and Korea (8) (Chang et al., manuscript in
process). A majority of patients in Korea (89%) had deflated
expander bag prior to radiation in a greater or lesser extent,
whereas 75.2% of physicians in the US responded that they do
not routinely deflate the expander bag. A recent retrospective
study of 49 patients in Korea found that RT-related complications
are significantly reduced in the maximal inflation group (29).
In this context, we changed our practice to maintain maximal
inflation at the time of RT, but this should be a subject of an
ongoing research.
This study has limitations inherent to any retrospective
studies. Effects of bolus and dose inhomogeneity on complication
rates were not observed in this study, however the analysis is
probably limited in this study cohort, where the maximum dose
was consistently controlled below 105–107%. Another caveat is
that implant size elected by Korean women are generally smaller
than their American counterparts similarly Korean women have
a lower body mass index than American women. Selection
bias, different median follow-up times between hypofractionated
and conventional fractionated RT, and unmeasured confounding
possibly existed and yielded exacerbated risk in the conventional
RT group. Since the actual rate of reconstruction-related
complications in this study is quite similar to that in previous
studies, we do not expect that it actually occurred. A longer
follow-up is necessary to estimate accurate complication rates
because it increases as the duration of patient follow-up
increases. Moreover, we attempted to adequately control surgical
confounders of complication by limiting the study eligibility to
patients who underwent the same procedures with ADM by two
experienced surgeons.
To our knowledge, this study is the first to demonstrate
radiation dose-response and complications, as well as the effect of
hypofractionated regimens and other radiation factors including
use of boost RT, RT technique, and tissue-equivalent bolus.
As a radiation technique, fractionation schedule, planning, and
delivery evolve, a number of factors increase the influence of
near Dmax on complications. Efforts to decrease radiation dose
by focusing either on selecting hypofractionated regimen or
modifying boost RT are likely to have a major effect. The
finding that multiple hypofractionated regimens yielded similar
treatment outcomes and late toxicity but varied acute toxicity
according to different regimens in patients with intact breast after
breast conservation surgery suggest that some hypofractionated
regimens have the potential to reduce complications in the
setting of breast reconstruction. Our results are hypothesis
generating, and confirmatory studies with external datasets are
mandatory. However, these results can provide a foundation
for future protocols to improve the outcomes of breast
reconstruction in post-mastectomy RT setting. On the basis of
our findings, we conducted multi-center retrospective studies
to validate our findings (KROG 18-04). We also initiated
a prospective multi-institutional study to evaluate patient-
reported outcomes in patients treated with breast reconstruction
and different fractionation regimens (NCT 03523078). For
ongoing and future trials, rigorous dose quality assurance and
modification of dose constraints could be considered as a
critically important component.
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